No Data
No Data
Earnings Preview: ASND to Report Financial Results Post-market on May 01
Ascendis Pharma to Report First Quarter 2025 Financial Results and Provide Business Update on May 1, 2025
European Equities Traded in the US as American Depositary Receipts Rise Sharply in Tuesday Trading
Express News | Ascendis Pharma A/S : RBC Initiates Coverage With Outperform Rating; Price Target $205
Ascendis Pharma (ASND) Receives a Buy From Evercore ISI
BofA Securities Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $192